All In Biotech

Drug Trial Radar · NCT01407263

Trial of Modifications to Radical Prostatectomy

A Randomized Trial of Modifications to Radical Prostatectomy

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 3,204 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,204

Actual

Start

Jul 2011

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate whether the following aspect of surgical technique influence outcome: Lymph node dissection. In some patients, scans taken before surgery show that a lymph node has cancer. Surgeons make sure to remove those affect lymph nodes and all other lymph nodes in the area. However, it is not known whether removing lymph nodes helps prostate cancer patients whose scans do not show positive nodes. In this study, patients with clear scans will either receive a lymph node dissection or not."

Conditions

  • Prostate Cancer

Interventions

  • Lymph node templateProcedure

    Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence. .No lymph nodes will be removed in patients randomized to the no PLND arm.

  • Transverse versus vertical closureProcedure

    Transverse versus vertical closure of the port site incision

  • antibiotic prophylaxisDrug

    One vs. three days of antibiotic prophylaxis at catheter removal

  • Hemostatic AgentDrug

    For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient-reported herniaTime frame: 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Cancer Center at Basking Ridge

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering Bergen (Consent Only)

    Montvale, New Jersey

  • Memorial Sloan Kettering Westchester

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)

    Uniondale, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.